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PTENgeneisconsideredoneofthemostmutatedtumorsuppressorgenesinhumancancer,andit’slikelytobecometheﬁrstonein
the near future. Since 1997, its involvement in tumor suppression has smoothly increased, up to the current importance. Germline
mutations of PTEN cause the PTEN hamartoma tumor syndrome (PHTS), which include the past-called Cowden, Bannayan-
Riley-Ruvalcaba, Proteus, Proteus-like, and Lhermitte-Duclos syndromes. Somatic mutations of PTEN have been observed in
glioblastoma, prostate cancer, and brest cancer cell lines, quoting only the ﬁrst tissues where the involvement has been proven.
The negative regulation of cell interactions with the extracellular matrix could be the way PTEN phosphatase acts as a tumor
suppressor. PTEN gene plays an essential role in human development. A recent model sees PTEN function as a stepwise gradation,
which can be impaired not only by heterozygous mutations and homozygous losses, but also by other molecular mechanisms,
such as transcriptional regression, epigenetic silencing, regulation by microRNAs, posttranslational modiﬁcation, and aberrant
localization. The involvement of PTEN function in melanoma and multistage skin carcinogenesis, with its implication in cancer
treatment, and the role of front oﬃce in diagnosing PHTS are the main reasons why the dermatologist should know about PTEN.
1 .PT ENGe ne :W h atI tI sandH o wI tW o rk s
PTEN stands for phosphatase and tensin homolog deleted
in chromosome 10, and it is considered one of the most
mutated tumor suppressor genes in human cancer. In the
near future, it is likely to become the ﬁrst one overcoming
the current leader, p53 gene [1]. The involvement of PTEN’s
alteration in tumorigenesis has been ﬁrst suspected and
subsequently proven in 1997 [2], when high frequency
of loss of heterozygosity (LOH) at 10q23 chromosome
band was observed in several human tumors. Furthermore,
the suppression of tumorigenesis in glioblastoma murine
cells by the wildtype chromosome 10 led to envision a
tumor suppressor gene mapping in 10q23. Such gene was
eventually isolated by the above-mentioned authors and
called PTEN. They detected homozygous deletions, frame
shift, or nonsense mutations in PTEN in 63% (5/8) of
glioblastoma cell lines, 100% (4/4) of prostate cancer cell
lines, and 10% (2/20) of breast cancer cell lines. Steck
et al. [3] independently isolated the same gene and called it
mutatedinmultipleadvancedcancers-1(MMAC-1).Indeed,
a common feature of PTEN somatic mutations, already
presented in 10q LOH, is the association with advanced-
stage tumors (mainly glial and prostate cancers), whereas
this is not true for endometrial cancer, being aﬀected equally
at all the stages. This has led to the suggestion that the
activation of PTEN is at an early stage in endometrial car-
cinogenesis, but later on in glial and prostatic carcinogenesis.
This mechanism is the cornerstone of the classical two-hit
Knudson’ hypothesis [4]: a single mutation in one homolog
of a tumor-suppressor gene is not suﬃcient to initiate tumor
growth; however, deletion or disabling of the allele on the
homologouschromosomeresultsinunregulatedcellgrowth.
Both sporadic and hereditary tumors can be explained by
suchmechanism.Insporadictumors,bothallelesarenormal
at conception; subsequently, a postzygotic mutation (ﬁrst
hit) in one cell creates the heterozygosity (one mutant and
one normal allele); thereafter, a deletion or a new mutation
(second hit) in the other allele of that cell provokes the
LOH, starting the uncontrolled tumor growth. In hereditary
tumors, the heterozygosity for mutant allele (ﬁrst hit) is
p r e s e n ta tc o n c e p t i o n ,a n di ss u ﬃcient that a postzygotic2 The Scientiﬁc World Journal
mutation (second hit) during life creates the LOH for the
onset of uncontrolled tumor growth.
Liaw et al. [5] found germline mutations of PTEN gene
in families with Cowden syndrome [6] (CS), showing the
function of tumor suppressor gene also in the germline. Fur-
thermore, germline PTEN mutations lead to increased breast
cancer incidence, but do not frequently cause familial breast
cancer [7], notwithstanding 10% of breast cancer cell lines
haveinactivatedPTEN[2,3].Recentlyithasbeenshownthat
PTEN loss is a common event in breast cancers caused by
BRCA1 deﬁciency [8]. Marsh et al. [9] deﬁned PTEN hamar-
toma tumor syndrome (PHTS) as a syndromic condition
including one or more hamartomas which has its biological
basis in a germline mutation of the PTEN gene. Following
such assumption, PHTS includes patients with the previ-
ous diagnosis of CS, Bannayan-Riley-Ruvalcaba syndrome
[10] (BRRS), Proteus syndrome [11] (PS), Proteus-like
syndrome [12] (PLS), and Lhermitte-Duclos syndrome [13]
(LDS).
Li et al. [2] have shown that PTEN gene is a human
cdc14 homolog, like CDC14A and CDC14B. The cdc14
gene is a key point for the progression of cell cycle in
Saccharomyces cerevisiae. Its protein acts in late nuclear divi-
sion preparing for subsequent DNA replication. The human
PTEN gene spans 103,207 bases, is made up of 9 exons,
and codes for a 1212-bp transcript and a 403-amino-acid
protein.
The PTEN product has the kinetic properties of dual-
speciﬁc phosphatases [14] and acts on G1 cell cycle pro-
gression through negative regulation of the PI3-kinase/Akt
or PKB signalling pathway [15]. PTEN is a member of
the protein-tyrosine phosphatase (PTP) gene superfamily
[2, 3]. These are genes consisting of conserved catalytic
domains, ﬂanked by noncatalytic regulatory sequences [16].
The PTP catalytic domains show a “signature motif,” which
is the canonical sequence HCXXGXXRS/T. Among the
PTP superfamily genes, a further split is made in “classic”
PTP (acting only towards phosphothyrosine residues) and
dual-speciﬁcity phosphatase families (dephosphorylating
phosphotyrosine, phosphoserine and/or phosphotreonine).
PTENisadual-speciﬁcityphosphatase.Thecatalyticdomain
of PTEN has been proven to be essential for its function,
which is lost following any mutation within the signature
motif [17].
PTEN gene in glioblastoma-derived cell lines regulates
hypoxia- and IGF-1-induced angiogenic gene expression by
regulating Akt activation of HIF-1 activity [18]. Restora-
tion of wild-type PTEN to glioblastoma cell lines lacking
functional PTEN ablates hypoxia and IGF-1 induction of
HIF-1-regulated genes. In addition, Akt activation leads
to HIF-1α stabilization, whereas PTEN attenuates hypoxia-
mediated HIF-1 α stabilization. Loss of PTEN during malig-
nant progression contributes to tumor expansion through
the deregulation of Akt activity and HIF-1-regulated gene
expression. PTEN abnormalities have been found also in
primary acute leukemias and non-Hodgkin’s lymphomas
[19].
PTEN and phosphorylated Akt levels are inversely cor-
related in the large majority of the examined samples,
suggesting that PTEN regulates phosphatidylinositol 3,4,5-
triphosphates and may play a role in apoptosis. Overex-
pression of PTEN inhibits cell migration, whereas antisense
PTEN enhances migration [20]. The phosphatase domain
of PTEN is essential because its inactivation does not allow
the downregulation of integrin-mediated cell spreading and
formation of focal adhesions, peculiar of wild-type PTEN.
Overexpression of focal adhesion kinase (FAK) partially
antagonizes the eﬀects of PTEN. Thus, the negative regula-
tion of cell interactions with the extracellular matrix could
be the way PTEN phosphatase acts as a tumor suppressor.
PTEN gene plays an essential role in human develop-
ment. Indeed, the additional eﬀect of three homozygotic
mutations together (e.g., mutations in both alleles) produces
early embryonic lethality in mice, whereas heterozygosis
(e.g., mutations in one allele) increases tumor incidence
[21–23]. Furthermore, PTEN antagonizes growth factor-
induced Shc phosphorylation and inhibits the MAP kinase
(MAPK) signalling pathway [24]. The way this inhibition is
accomplishediscurrentlyunderstoodasasuppressionbythe
PTEN protein phosphatase activity [25].
The function of PTEN gene and the way its mutation
can cause a disease can barely be understood if one does not
see the PTEN protein inside the PI3K/Akt/mTOR signalling
pathway [26]( Figure 1). The activation of phosphoinositide
3  kinase (PI3K) is the primary event in this pathway
[27]. This can occur from several growth factor receptors
(GFRs), such as PDGFR, EGFR, FGFR, IGF-1R, VEGFR,
IL-R, interferon receptors (IF-Rs), integrin receptors, and
the Ras pathway [28–30]. The major role of PI3K is
the phosphorylation of phosphatidylinositol (4,5) P (PIP2)
to phosphatidylinositol (3,4,5) P (PIP3). PIP3 binds and
translocates Akt near the cell membrane where it can be
phosphorylatedandactivatedbyphosphatidylinositol(3,4,5)
P-dependent kinase 1 (PDK1) and phosphatidylinositol
(3,4,5) P-dependent kinase 2 (PDK2). Akt has several down-
stream eﬀectors which mediate its ability to promote cell
survival and growth. Then, activation of PI3K/Akt pathway
is observed in several human cancers. PTEN is the antagonist
of PI3K because it dephosphorylates PIP3 to PIP2. The
PI3K/PTEN imbalance, caused for instance by a mutation
of PTEN, is then responsible for the progression to human
cancer.
Salmena et al. [1] have recently proposed a model for
the causes and consequences of PTEN loss. While retinoblas-
toma (RB) gene has been the foundation of the Knudson’s
hypothesis [4], showing that only the homozygous loss of
such gene can start the retinoblastoma initiation, PTEN
behaves in a diﬀerent way. There is compelling evidence in
miceconﬁrmingPTENasahaploinsuﬃcienttumorsuppres-
sor gene: loss of one allele leads to the progression of a lethal
polyclonal autoimmune disorder [31]; epithelial cancers,
such as prostate cancer, are driven by PTEN heterozygosity
[32]; cellular levels of PTEN protein inversely correlate with
the occurrence of invasive prostate cancer [1]. Consequently,
functional loss of one PTEN allele is critical for the onset of
cancer in mice. Things in humans are little less compelling,
but the evidence is growing. The association between PTEN
heterozygous germline mutations and the so-called PHTSThe Scientiﬁc World Journal 3
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Figure 1: Pathway involving the PTEN protein.
is the ﬁrst proof. Further evidence for haploinsuﬃciency is
supportedbythefollowingobservations:sometumorsarisen
in patients with CS do not show biallelic mutations of PTEN
gene [33]; primary prostate cancers are associated with loss
or alteration of one PTEN allele in 70% of cases [34],
whereashomozygousdeletionispresentin10%ofcases[35];
the occurrence of monoallelic mutation of PTEN in breast
cancer is much more frequent (30–40% versus 5%) than that
of biallelic loss [36–38]. Besides the above-mentioned proofs
of the contribution of PTEN haploinsuﬃciency to tumor
progression and cancer syndromes, the identiﬁcation of CS
and tumor-derived PTEN mutations preserving partial or
full PTEN lipid phosphatase function [39] allows the notion
that even minor impairments of PTEN function can lead
to cancer. The model of Santena et al. [1] springs from
the above results: the loss of PTEN function, caused not
only by classical genetic mutations leading to heterozygous
(50% of function) or homozygous (0% of function) loss, but
also by other molecular mechanisms, such as transcriptional
regression, epigenetic silencing, regulation by microRNAs,
posttranslational modiﬁcation, and aberrant localization,
can lead to subtle and/or dramatic losses of PTEN function,
behaving as a stepwise gradation of function. An unexpected
result has been put forward by Chen et al. [40], who
studied the relationship between PTEN dose and tumor
progression in mouse models of prostate speciﬁc loss of
P T E N :c o m p l e t ea c u t el o s so fP T E Np r o m o t e das t r o n g
senescence response opposing tumor progression. Campisi
and d’Adda di Fagagna [41] interpreted senescence as an
antitumor mechanism set oﬀ by tumor suppressor genes in
response to triggers including DNA damage and oncogene
activation.
While heterozygous and homozygous mutations are now
widely understood, the other molecular mechanisms deserve
some clariﬁcation. We will do so, showing that all these
mechanisms have a signiﬁcant impact in the way PTEN
functions, as a model of tumor suppressor gene.
While transforming growth factor β (TGFβ)w a sc o n -
sidered the single transcriptional regulator of PTEN gene in
1997 [42], acting in a negative way, today the story is much
more complicated. Several factors have been discovered
to upregulate, such as early growth-regulated transcription4 The Scientiﬁc World Journal
factor-1 (EGR-1) [43] which is a downstream eﬀector of
Insulin-like growth factor 2 (IGF-2) [44], and peroxisome
proliferation-activated receptor-γ (PPAR-γ)[ 45], p53 [46],
and MYC [47], or downregulate PTEN, such as c-Jun [48],
NFκB[ 49], and HES-1 [47]. Furthermore, a peculiar way
of PTEN’s transcriptional regulation is that of NOTCH1,
which increases the transcription of PTEN at least in two
fashions: activating MYC [47] or repressing CBF-1 [50, 51],
which is a downregulator of PTEN. Conversely, NOTCH1
repressesPTEN’stranscription,activatingtheknownPTEN’s
downregulator HES-1 [47]. Another complication of the
action of NOTCH1 on PTEN is the tissue speciﬁcity, which
allows upregulation or downregulation according to the
involved tissues.
Epigenetic silencing means that the function of a gene
is broken, not by means of DNA mutations, but for other
mechanisms, which are mainly the DNA methylation of the
gene promoter and the histone modiﬁcation. The promoter
methylation of PTEN gene has been associated to several
cancers [52–54].
MicroRNAs (miRNAs) are single-stranded RNAs, made
upofafew(usually22)nucleotides,whichrepressthemRNA
translation. One of the most studied miRNAs, miR-21, has
been reported as a repressor of PTEN, exerting its oncogenic
activity, at least partially, downregulating PTEN expression
[55–59].
Posttranslational modiﬁcation is a further way of reg-
ulation of the action of a gene, without any change in
its DNA. It can be deﬁned as the chemical modiﬁcation
of a protein after its translation. The four main chemical
reactions are phosphorylation, acetylation, oxidation, and
ubiquitination. PTEN has six phosphorylation sites [1],
which have been involved in the modulation of its tumor
suppressor functions, subcellular distribution, and stability.
They are Threonine 366 (Thr366), Serine 370 (Ser370),
Ser385, Ser380, Thr382, and Thr383. The last three are
collectively referred to as the STT cluster, which has the
most important eﬀects on PTEN function. The wild-type
or phosphorylated STT cluster is maintained to stabilize
PTEN in a closed state, whereas the mutation at these phos-
phorylation sites opens the protein conformation, making
it less stable [60]. A dephosphorylation of the STT cluster
is currently considered a common way leading to cancer
activation [61]. PTEN interacts with the nuclear histone
acetyltransferase-associatedPCAFprotein,promotingPTEN
acetylation at Lysine 125 (Lys125) and Lys128 sites, which
in turn negatively regulates PTEN catalytic activity [62].
What is now called reactive oxygen species (ROS), which is
made of oxygen ions, free radical, and peroxides, are very
small molecules sharing a high reactivity due to presence
of unpaired valence shell electrons. ROS modulates PTEN
catalytic activity by oxidative-stress-induced formation of a
disulﬁde bond between the active site cysteine 124 (Cys124)
and Cys71 [63]. Ubiquitin [64] is a highly conserved
regulatory protein that is widely (ubiquitously) expressed
in eukaryotes. Ubiquitination refers to the posttranslational
modiﬁcation of a protein by the covalent attachment (via an
isopeptide bond) of one or more ubiquitin monomers. The
mostprominentfunctionofubiquitinislabelingproteinsfor
proteasomal degradation. Proteasome inhibition increases
the half-life of PTEN [65], and the exposure of human
bronchial cells to zinc ions promotes ubiquitin-dependent
degradation of PTEN [66], but inhibitors of the proteasome
may destabilize PTEN [67]. Notwithstanding such incoher-
ent results, ubiquitination to lysine 13 (Lys13) and Lys289 is
needed for the nuclear-cytoplasmic shuttling of PTEN [68].
SuchlastfactimpliesthenotionthatPTENproteincanmove
from cytoplasm to nucleus, and backward. However, this was
notclearattheverybeginning,wheneveryonethoughtitwas
exclusively localized to the cytoplasm. PTEN is abundantly
localizedinthenucleusofprimary,diﬀerentiated,andresting
cells, while there is a sharp decrease in cancer cells [69–72].
Cell cycle stage and diﬀerentiation status are, consequently,
related to PTEN localization. The fact that PTEN protein
is localized in the nucleus, besides the cytoplasm, has an
important role in the tumor suppressor function of such
protein. This is proven by the report of patients with
more aggressive tumors, such as esophageal squamous cell
carcinoma [73], cutaneous melanoma [74, 75], colorectal
cancer [76], and pancreatic islet cell tumors [72], having
their PTEN protein absent in the nucleus.
2.Why Should the Dermatologist
Know aboutPTEN?
Besides using PTEN as a model for genetic disease, the der-
matologist should deepen his knowledge of such fascinating
pathway for some very practical reasons.
First of all, think of melanoma. Approximately 70% of
melanomas have elevated Akt3 signaling both for increased
gene copy number and PTEN loss. Consequently, the target-
ing of (V600E)B-Raf and Akt3 signalling can prevent or treat
cutaneous melanocytic lesions. The development of agents
speciﬁcally targeting these proteins would be very useful,
because they have fewer side eﬀects than those inhibiting
both normal and mutant B-Raf protein or targeting all three
Akt isoforms. Recently [77], a nanoliposomal-ultrasound-
mediated approach reported for delivering small interfering
RNA (siRNA) speciﬁcally targeting (V600E)B-Raf and Akt3
into melanocytic tumors present in skin to retard melanoma
development. Novel cationic nanoliposomes stably encap-
sulate siRNA targeting (V600E)B-Raf or Akt3, providing
protection from degradation and facilitating entry into
melanoma cells to decrease expression of these proteins.
Low-frequency ultrasound using a lightweight four-cymbal
transducer array enables penetration of nanoliposomal-
siRNA complex throughout the epidermal and dermal layers
of laboratory-generated or animal skin. Nanoliposomal-
mediated siRNA targeting of (V600E)B-Raf and Akt3 led to
a cooperatively acting approximately 65% decrease in early
or invasive cutaneous melanoma compared with inhibition
of each singly with negligible associated systemic toxicity.
Thus, cationic nanoliposomes loaded with siRNA targeting
(V600E)B-Raf and Akt3 provide an eﬀective approach
for targeted inhibition of early or invasive cutaneous
melanomas. Furthermore, it is currently thought that the
progression of human cutaneous melanomas behaves in aThe Scientiﬁc World Journal 5
stepwise fashion, due to accumulating genetic and epigenetic
alterations. The combination of PTEN deﬁciency and Braf
activation induces a melanoma in-situ-like phenotype with-
out dermal invasion. Further addition of cell autonomous
TGF-β activation in the context of PTEN deﬁciency and
Braf activation promotes dermal invasion in skin cultures
without signiﬁcantly promoting proliferation in vitro and in
vivo. This proinvasive phenotype of cell autonomous TGF-
β activation is genetic context dependent, as hyperactivating
the TGF-β type I receptor without PTEN deﬁciency and Braf
activation failed to induce an invasive behavior. Evidence of
genetic interactions among PTEN deﬁciency, Braf activation,
and cell autonomous TGF-β activation shows that distinct
stages of human melanoma are genetically tractable in the
proper tissue architecture [78].
Secondly, multistage skin carcinogenesis is prone to
gene synergism. The ablation of PTEN function in mouse
epidermis expressing activated Fos leads to hyperplasia,
hyperkeratosis, and tumors that move forward to highly
diﬀerentiated keratoacanthomas, rather than to carcinomas
[79].
Thirdly, the dermatologist can be the front oﬃce in
diagnosing a PHTS. Acral papular neuromatosis [80]a n d
mucocutaneous neuromas [81] can be the ﬁrst sign of a
disease caused by a PTEN mutation. Katona et al. [82]
analysed a series of patients aﬀected by mycosis fungoides,
showingthatLOHstudiesarearobustmethodforevaluating
genetic abnormalities in mycosis fungoides, and several
loci associated with the PTEN appear to be associated
with progression from plaque to tumor stage. It has been
shown that PTEN was signiﬁcantly higher in depigmented
epidermis, implying that vitiliginous keratinocytes may be
more susceptible to TNF-alpha-mediated apoptosis through
impaired Akt and NF-kappaB activation. Keratinocytes
showing impaired Akt activation demonstrated increased
apoptosis with less activation of NF-kappaB. Thus, reduced
activation of NF-kappaB via impaired PI3K/Akt activation
under increased TNF-alpha levels could result in increased
apoptosis of vitiliginous keratinocytes [83].
Finally, the pathogenic role of mutated PTEN involves
some conditions collectively called PTEN hamartoma tumor
syndrome (PHTS) [84, 85], such as Cowden syndrome
[86],Bannayan-Riley-Ruvalcabasyndrome(BRRS)[87],and
Proteus syndrome (PS) [88].
Such rare diseases highlight tumoral degeneration in
many body organs. Aﬀected patients show usually variable
degrees of intellective disability. The cutaneous surface
of PHTS patients leads one to suspect the disease being
present, many times in a peculiar way. Main examples
are speckled penis in BRRS [87]( Figure 2), plantar cere-
briform hyperplasia in 70–80% of PS patients [88, 89]
(Figure 3), and three or more trichilemmomas in CS
[86].
The spectrum of clinical ﬁndings associated with PTEN
tumor suppressor gene germline mutations includes also
mucocutaneous neuromas, as reported by Shaﬀer et al., who
stated that this is an underrecognized manifestation of the
gene [81]. These are only some reasons why the knowledge
ofPTENis very much needed forthedermatologist, not only
Figure 2: Speckled penis in a patient aﬀected by Bannayan-Riley-
Ruvalcaba syndrome.
Figure 3: Cerebriform plantar hyperplasia in a girl aﬀected by
Proteus syndrome.
for his/her culture, but also for practical issues, such as a
targeted therapy in the near future.
Conﬂict of Interests
The authors have no conﬂict of interests to declare.
References
[1] L. Salmena, A. Carracedo, and P. P. Pandolﬁ, “Tenets of PTEN
tumor suppression,” Cell, vol. 133, no. 3, pp. 403–414, 2008.
[2] J. Li, C. Yen, D. Liaw et al., “PTEN, a putative protein
tyrosine phosphatase gene mutated in human brain, breast,
and prostate cancer,” Science, vol. 275, no. 5308, pp. 1943–
1947, 1997.
[ 3 ]P .A .S t e c k ,M .A .P e r s h o u s e ,S .A .J a s s e re ta l . ,“ I d e n t i ﬁ c a t i o n
of a candidate tumour suppressor gene, MMAC1, at chromo-
some 10q23.3 that is mutated in multiple advanced cancers,”
Nature Genetics, vol. 15, no. 4, pp. 356–362, 1997.
[4] A. G. Knudson, “Mutation and cancer: statistical study
of retinoblastoma,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 68, no. 4, pp. 820–
823, 1971.
[5] D. Liaw, D. J. Marsh, J. Li et al., “Germline mutations of the
PTENgeneinCowdendisease,aninheritedbreastandthyroid
cancer syndrome,” Nature Genetics, vol. 16, no. 1, pp. 64–67,
1997.
[ 6 ]P .E .W e a r y ,R .J .G o r l i n ,W .C .G e n t r y ,J .E .C o m e r ,a n dK .E .
Greer, “Multiple hamartoma syndrome (Cowden’s disease),”
Archives of Dermatology, vol. 106, no. 5, pp. 682–690, 1972.6 The Scientiﬁc World Journal
[7] J. Chen, P. Lindblom, and A. Lindblom, “A study of the
PTEN/MMAC1 gene in 136 breast cancer families,” Human
Genetics, vol. 102, no. 1, pp. 124–125, 1998.
[8] L. H. Saal, S. K. Gruvberger-Saal, C. Persson et al., “Recurrent
gross mutations of the PTEN tumor suppressor gene in breast
cancerswithdeﬁcientDSBrepair,”Nature Genetics,vol.40,no.
1, pp. 102–107, 2008.
[ 9 ]D .J .M a r s h ,J .B .K u m ,K .L .L u n e t t ae ta l . ,“ P T E Nm u t a t i o n
spectrum and genotype-phenotype correlations in Bannayan-
Riley-Ruvalcaba syndrome suggest a single entity with Cow-
den syndrome,” Human Molecular Genetics, vol. 8, no. 8, pp.
1461–1472, 1999.
[10] M. M. Cohen Jr., “Bannayan-Riley-Ruvalcaba Syndrome:
renaming three formerly recognized syndromes as one etio-
logic entity,” American Journal of Medical Genetics, vol. 35, no.
2, pp. 291–2292, 1990.
[11] H. R. Wiedemann, G. R. Burgio, P. Aldenhoﬀ,J .K u n z e ,H .
J. Kaufmann, and E. Schirg, “The proteus syndrome. Partial
gigantism of the hands and/or feet, nevi, hemihypertrophy,
subcutaneous tumors, microcephaly and other skull anoma-
lies and possible accelerated growth and visceral aﬀections,”
European Journal of Pediatrics, vol. 140, pp. 5–12, 1983.
[ 1 2 ]X .P .Z h o u ,D .J .M a r s h ,H .H a m p e l ,J .B .M u l l i k e n ,O .G i m m ,
and C. Eng, “Germline and germline mosaic PTEN mutations
associated with a Proteus-like syndrome of hemihypertrophy,
lower limb asymmetry, arteriovenous malformations and
lipomatosis,”HumanMolecularGenetics,vol.9,no.5,pp.765–
768, 2000.
[13] H. M. Dastur, S. K. Pandya, and D. H. Deshpande, “Diﬀuse
cerebellar hypertrophy. (Lhermitte Duclos disease),” Neurol-
ogy India, vol. 23, no. 1, pp. 53–56, 1975.
[14] M. P. Myers, J. P. Stolarov, C. Eng et al., “P-TEN, the tu-
mor suppressor from human chromosome 10q23, is a dual-
speciﬁcity phosphatase,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 94, no. 17, pp.
9052–9057, 1997.
[15] D. M. Li and H. Sun, “PTEN/MMAC1/TEP1 suppresses the
tumorigenicity and induces G1 cell cycle arrest in human
glioblastoma cells,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 95, no. 26, pp.
15406–15411, 1998.
[ 1 6 ] J .M .D e n u ,J .A .S t u c k e y ,M .A .S a p e r ,a n dJ .E .D i x o n ,“ F o r m
and function in protein dephosphorylation,” Cell, vol. 87, no.
3, pp. 361–364, 1996.
[17] M. P. Myers and N. K. Tonks, “PTEN: sometimes taking it oﬀ
can be better than putting it on,” American Journal of Human
Genetics, vol. 61, no. 6, pp. 1234–1238, 1997.
[18] W. Zundel, C. Schindler, D. Haas-Kogan et al., “Loss of
PTEN facilitates HIF-1-mediated gene expression,” Genes and
Development, vol. 14, no. 4, pp. 391–396, 2000.
[19] P. L. M. Dahia, R. C. T. Aguiar, J. Alberta et al., “PTEN
is inversely correlated with the cell survival factor Akt/PKB
and is inactivated via multiple mechanisms in haematological
malignancies,” Human Molecular Genetics,v o l .8 ,n o .2 ,p p .
185–193, 1999.
[20] M.Tamura,J.Gu,K.Matsumoto,S.I.Aota,R.Parsons,andK.
M. Yamada, “Inhibition of cell migration, spreading, and focal
adhesions by tumor suppressor PTEN,” Science, vol. 280, no.
5369, pp. 1614–1617, 1998.
[21] A. Di Cristofano, B. Pesce, C. Cordon-Cardo, and P. P.
Pandolﬁ, “Pten is essential for embryonic development and
tumour suppression,” Nature Genetics, vol. 19, no. 4, pp. 348–
355, 1998.
[ 2 2 ]A .S u z u k i ,J .L .d eL aP o m p a ,V .S t a m b o l i ce ta l . ,“ H i g h
cancer susceptibility and embryonic lethality associated with
mutation of the PTEN tumor suppressor gene in mice,”
Current Biology, vol. 8, no. 21, pp. 1169–1178, 1998.
[23] K. Podsypanina, L. H. Ellenson, A. Nemes et al., “Mutation
of Pten/Mmac1 in mice causes neoplasia in multiple organ
systems,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 96, no. 4, pp. 1563–1568, 1999.
[24] L. P. Weng, W. M. Smith, J. L. Brown, and C. Eng, “PTEN
inhibits insulin-stimulated MEK/MAPK activation and cell
growth by blocking IRS-1 phosphorylation and IRS-1/Grb-
2/Sos complex formation in a breast cancer model,” Human
Molecular Genetics, vol. 10, no. 6, pp. 605–616, 2001.
[ 2 5 ]L .P .W e n g ,J .L .B r o w n ,K .M .B a k e r ,M .C .O s t r o w s k i ,a n dC .
Eng, “PTEN blocks insulin-mediated ETS-2 phosphorylation
through MAP kinase, independently of the phosphoinositide
3-kinase pathway,” Human Molecular Genetics, vol. 11, no. 15,
pp. 1687–1696, 2002.
[26] H. B. Newton, “Molecular neuro-oncology and development
of targeted therapeutic strategies for brain tumors. Part
2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis,”
ExpertReviewofAnticancerTherapy,vol.4,no.1,pp.105–128,
2004.
[27] I. Vivanco and C. L. Sawyers, “The phosphatidylinositol
3-kinase-AKT pathway in human cancer,” Nature Reviews
Cancer, vol. 2, no. 7, pp. 489–501, 2002.
[28] K. A. Martin and J. Blenis, “Coordinate regulation of trans-
l a t i o nb yt h eP I3 - k i n a s ea n dm T O Rp a t h w a y s , ”Advances in
Cancer Research, vol. 86, pp. 1–39, 2002.
[29] M. P. Wymann and L. Pirola, “Structure and function of
phosphoinositide 3-kinases,” Biochimica et Biophysica Acta,
vol. 1436, no. 1-2, pp. 127–150, 1998.
[30] L. E. Rameh and L. C. Cantley, “The role of phosphoinositide
3-kinase lipid products in cell function,” The Journal of
Biological Chemistry, vol. 274, no. 13, pp. 8347–8350, 1999.
[31] A. Di Cristofano, P. Kotsi, Y. F. Peng, C. Cordon-Cardo, K.
B. Elkon, and P. P. Pandolﬁ, “Impaired Fas response and
autoimmunity in Pten(+/−) mice,” Science, vol. 285, no. 5436,
pp. 2122–2125, 1999.
[32] A.DiCristofano,M.DeAcetis,A.Koﬀ, C.Cordon-Cardo,and
P. P Pandolﬁ, “Pten and p27KIP1 cooperate in prostate cancer
tumor suppression in the mouse,” Nature Genetics, vol. 27, no.
2, pp. 222–224, 2001.
[33] P. L. M. Dahia, “PTEN, a unique tumor suppressor gene,”
Endocrine-Related Cancer, vol. 7, no. 2, pp. 115–129, 2000.
[ 3 4 ] I .C .G r a y ,L .M .D .S t e w a r t ,S .M .A .P h i l l i p se ta l . ,“ M u t a t i o n
and expression analysis of the putative prostate tumour-
suppressor gene PTEN,” British Journal of Cancer, vol. 78, no.
10, pp. 1296–1300, 1998.
[35] Y. E. Whang, X. Wu, H. Suzuki et al., “Inactivation of
the tumor suppressor PTEN/MMAC1 in advanced human
prostate cancer through loss of expression,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 95, no. 9, pp. 5246–5250, 1998.
[36] I. U. Ali, L. M. Schriml, and M. Dean, “Mutational spectra
of PTEN/MMAC1 gene: a tumor suppressor with lipid
phosphatase activity,” Journal of the National Cancer Institute,
vol. 91, no. 22, pp. 1922–1932, 1999.
[ 3 7 ] S .Bo s e ,S .I .W a n g,M .B .T e rry ,H .H i b s h oo s h ,a n dR .P a r s o n s ,
“Allelic loss of chromosome 10q23 is associated with tumor
progressioninbreastcarcinomas,”Oncogene,v ol.17,no .1,pp .
123–127, 1998.
[38] H. E. Feilotter, V. Coulon, J. L. McVeigh et al., “Analysis of
the 10q23 chromosomal region and the PTEN gene in humanThe Scientiﬁc World Journal 7
sporadic breast carcinoma,” British Journal of Cancer, vol. 79,
no. 5-6, pp. 718–723, 1999.
[39] K. A. Waite and C. Eng, “Protean PTEN: form and function,”
American Journal of Human Genetics, vol. 70, no. 4, pp. 829–
844, 2002.
[ 4 0 ] Z .C h e n ,L .C .T r o t m a n ,D .S h a ﬀer et al., “Crucial role of p53-
dependent cellular senescence insuppressionofPten-deﬁcient
tumorigenesis,” Nature, vol. 436, no. 7051, pp. 725–730, 2005.
[41] J. Campisi and F. d’Adda Di Fagagna, “Cellular senescence:
when bad things happen to good cells,” Nature Reviews
Molecular Cell Biology, vol. 8, no. 9, pp. 729–740, 2007.
[42] D. M. Li and H. Sun, “TEP1, encoded by a candidate tumor
suppressor locus, is a novel protein tyrosine phosphatase
regulated by transforming growth factor β,” Cancer Research,
vol. 57, no. 11, pp. 2124–2129, 1997.
[43] T. Virolle, E. D. Adamson, V. Baron et al., “The Egr-1 tran-
scription factor directly activates PTEN during irradiation-
induced signalling,” Nature Cell Biology, vol. 3, no. 12, pp.
1124–1128, 2001.
[44] R. A. Moorehead, C. V. Hojilla, I. De Belle et al., “Insulin-like
growth factor-II regulates PTEN expression in the mammary
gland,”TheJournalofBiologicalChemistry,vol.278,no.50,pp.
50422–50427, 2003.
[45] L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith, and C. H.
Macphee, “Tumor suppressor and anti-inﬂammatory actions
of PPARγ agonists are mediated via upregulation of PTEN,”
Current Biology, vol. 11, no. 10, pp. 764–768, 2001.
[46] V. Stambolic, D. MacPherson, D. Sas et al., “Regulation of
PTEN transcription by p53,” Molecular Cell,v o l .8 ,n o .2 ,p p .
317–325, 2001.
[47] T. Palomero, M. L. Sulis, M. Cortina et al., “Mutational loss
of PTEN induces resistance to NOTCH1 inhibition in T-cell
leukemia,” Nature Medicine, vol. 13, no. 10, pp. 1203–1210,
2007.
[48] K.Hettinger,F.Vikhanskaya,M.K.Pohetal.,“c-Junpromotes
cellular survival by suppression of PTEN,” Cell Death and
Diﬀerentiation, vol. 14, no. 2, pp. 218–229, 2007.
[49] D. Xia, H. Srinivas, Y. H. Ahn et al., “Mitogen-activated
protein kinase kinase-4 promotes cell survival by decreasing
PTEN expression through an NFκB-dependent pathway,” The
Journal of Biological Chemistry, vol. 282, no. 6, pp. 3507–3519,
2007.
[ 5 0 ] W .H .C h a p p e l l ,T .D .G r e e n ,J .D .S p e n g e m a n ,J .A .
M c C u b r e y ,S .M .A k u l a ,a n dF .E .B e rt ra n d ,“ I n c r e a s e dp r o t e i n
expression of the PTEN tumor suppressor in the presence of
constitutively active notch-1,” Cell Cycle, vol. 4, no. 10, pp.
1389–1395, 2005.
[ 5 1 ]J .T .W h e l a n ,S .L .F o r b e s ,a n dF .E .B e r t r a n d ,“ C B F - 1( R B P -
Jκ) binds to the PTEN promoter and regulates PTEN gene
expression,” Cell Cycle, vol. 6, no. 1, pp. 80–84, 2007.
[52] J. M. Garc´ ıa, J. Silva, C. Pe˜ na et al., “Promoter methylation
of the PTEN gene is a common molecular change in breast
cancer,” Genes Chromosomes and Cancer,v o l .4 1 ,n o .2 ,p p .
117–124, 2004.
[ 5 3 ]A .G o e l ,C .N .A r n o l d ,D .N i e d z w i e c k ie ta l . ,“ F r e q u e n t
inactivation of PTEN by promoter hypermethylation in
microsatellite instability-high sporadic colorectal cancers,”
Cancer Research, vol. 64, no. 9, pp. 3014–3021, 2004.
[ 5 4 ] Y .H .K a n g ,S .L .H y e ,a n dH .K .W o o ,“ P r o m o t e rm e t h y l a t i o n
and silencing of PTEN in gastric carcinoma,” Laboratory
Investigation, vol. 82, no. 3, pp. 285–291, 2002.
[55] F. Meng, R. Henson, M. Lang et al., “Involvement of human
micro-RNA in growth and response to chemotherapy in
human cholangiocarcinoma cell lines,” Gastroenterology, vol.
130, no. 7, pp. 2113–2129, 2006.
[56] F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T.
Jacob, and T. Patel, “MicroRNA-21 regulates expression of
the PTEN tumor suppressor gene in human hepatocellular
cancer,” Gastroenterology, vol. 133, no. 2, pp. 647–658, 2007.
[ 5 7 ]J .A .C h a n ,A .M .K r i c h e v s k y ,a n dK .S .K o s i k ,“ M i c r o R N A - 2 1
isanantiapoptoticfactorinhumanglioblastomacells,”Cancer
Research, vol. 65, no. 14, pp. 6029–6033, 2005.
[ 5 8 ]M .L .S i ,S .Z h u ,H .W u ,Z .L u ,F .W u ,a n dY .Y .M o ,“ m i R - 2 1 -
mediated tumor growth,” Oncogene, vol. 26, no. 19, pp. 2799–
2803, 2007.
[59] S. Volinia, G. A. Calin, C. G. Liu et al., “A microRNA expres-
sion signature of human solid tumors deﬁnes cancer gene
targets,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 103, no. 7, pp. 2257–2261, 2006.
[60] N. R. Leslie and C. P. Downes, “PTEN function: how normal
cells control it and tumour cells lose it,” Biochemical Journal,
vol. 382, no. 1, pp. 1–11, 2004.
[61] F. Vazquez, S. R. Grossman, Y. Takahashi, M. V. Rokas, N.
Nakamura, and W. R. Sellers, “Phosphorylation of the PTEN
tail acts as an inhibitory switch by preventing its recruitment
into a protein complex,” The Journal of Biological Chemistry,
vol. 276, no. 52, pp. 48627–48630, 2001.
[62] K. Okumura, M. Mendoza, R. M. Bachoo, R. A. DePinho,
W. K. Cavenee, and F. B. Furnari, “PCAF modulates PTEN
activity,” The Journal of Biological Chemistry, vol. 281, no. 36,
pp. 26562–26568, 2006.
[63] S. R. Lee, K. S. Yang, J. Kwon, C. Lee, W. Jeong, and S. G.
Rhee, “Reversible inactivation of the tumor suppressor PTEN
by H2O2,” The Journal of Biological Chemistry, vol. 277, no. 23,
pp. 20336–20342, 2002.
[64] D. Nandi, P. Tahiliani, A. Kumar, and D. Chandu, “The
ubiquitin-proteasome system,” Journal of Biosciences, vol. 31,
no. 1, pp. 137–155, 2006.
[65] J. Torres and R. Pulido, “The tumor suppressor PTEN is
phosphorylated by the protein kinase CK2 at its C terminus.
Implications for PTEN stability to proteasome-mediated
degradation,” The Journal of Biological Chemistry, vol. 276, no.
2, pp. 993–998, 2001.
[66] W. Wu, X. Wang, W. Zhang et al., “Zinc-induced PTEN pro-
tein degradation through the proteasome pathway in human
airwayepithelialcells,”TheJournalofBiologicalChemistry,vol.
278, no. 30, pp. 28258–28263, 2003.
[67] Y. Tang and C. Eng, “p53 down-regulates phosphatase and
tensinhomologuedeleted onchromosome10proteinstability
partially through caspase-mediated degradation in cells with
proteasome dysfunction,” Cancer Research, vol. 66, no. 12, pp.
6139–6148, 2006.
[68] L. C. Trotman, X. Wang, A. Alimonti et al., “Ubiquitination
regulates PTEN nuclear import and tumor suppression,” Cell,
vol. 128, no. 1, pp. 141–156, 2007.
[69] O .Gimm,A.P erren,L.P .W engetal.,“Diﬀerentialnuclearand
cytoplasmic expression of PTEN in normal thyroid tissue, and
benign and malignant epithelial thyroid tumors,” American
Journal of Pathology, vol. 156, no. 5, pp. 1693–1700, 2000.
[70] M. E. Ginn-Pease and C. Eng, “Increased nuclear phosphatase
and tensin homologue deleted on chromosome 10 is associ-
ated with G0-G1 in MCF-7 cells,” Cancer Research, vol. 63, no.
2, pp. 282–286, 2003.
[71] M. B. Lachyankar, N. Sultana, C. M. Schonhoﬀ et al., “A
role for nuclear PTEN in neuronal diﬀerentiation,” Journal of
Neuroscience, vol. 20, no. 4, pp. 1404–1413, 2000.8 The Scientiﬁc World Journal
[72] A. Perren, P. Komminoth, P. Saremaslani et al., “Mutation
and expression analyses reveal diﬀerential subcellular com-
partmentalization of PTEN in endocrine pancreatic tumors
compared to normal islet cells,” American Journal of Pathology,
vol. 157, no. 4, pp. 1097–1103, 2000.
[73] M. Tachibana, M. Shibakita, S. Ohno et al., “Expression and
prognostic signiﬁcance of PTEN product protein in patients
withesophagealsquamouscellcarcinoma,”Cancer,vol.94,no.
7, pp. 1955–1960, 2002.
[74] D. C. Whiteman, X. P. Zhou, M. C. Cummings, S. Pavey,
N. K. Hayward, and C. Eng, “Nuclear PTEN expression
and clinicopathologic features in a population-based series
of primary cutaneous melanoma,” International Journal of
Cancer, vol. 99, no. 1, pp. 63–67, 2002.
[75] X. P. Zhou, O. Gimm, H. Hampel, T. Niemann, M. J.
Walker, and C. Eng, “Epigenetic PTEN silencing in malignant
melanomas without PTEN mutation,” American Journal of
Pathology, vol. 157, no. 4, pp. 1123–1128, 2000.
[76] X. P. Zhou, A. Loukola, R. Salovaara et al., “PTEN mutational
spectra, expression levels, and subcellular localization in
microsatellite stable and unstable colorectal cancers,” Ameri-
can Journal of Pathology, vol. 161, no. 2, pp. 439–447, 2002.
[77] M. A. Tran, R. Gowda, A. Sharma et al., “Targeting V600EB-
Raf and Akt3 using nanoliposomal-small interfering RNA
inhibits cutaneous melanocytic lesion development,” Cancer
Research, vol. 68, no. 18, pp. 7638–7649, 2008.
[ 7 8 ]R .S .L oa n dO .N .W i t t e ,“ T r a n s f o r m i n gg r o w t hf a c t o r - β
activation promotes genetic context-dependent invasion of
immortalized melanocytes,” Cancer Research, vol. 68, no. 11,
pp. 4248–4257, 2008.
[79] D. Yao, C. L. Alexander, J. A. Quinn, W. C. Chan, H. Wu, and
D. A. Greenhalgh, “Fos cooperation with PTEN loss elicits
keratoacanthoma not carcinoma, owing to p53/p21WAF-
induced diﬀerentiation triggered by GSK3β inactivation and
reduced AKT activity,” Journal of Cell Science, vol. 121, no. 10,
pp. 1758–1769, 2008.
[80] M. Ferran, E. Bussaglia, C. Lazaro, X. Matias-Guiu, and R. M.
Pujol, “Acral papular neuromatosis: an early manifestation of
Cowden syndrome,” British Journal of Dermatology, vol. 158,
no. 1, pp. 174–176, 2008.
[81] J.V.Schaﬀe r ,H.K amino ,A.W itkie wicz,J .M.M cN iﬀ,a ndS.J .
Orlow,“Mucocutaneousneuromas:anunderrecognizedman-
ifestation of PTEN hamartoma-tumor syndrome,” Archives of
Dermatology, vol. 142, no. 5, pp. 625–632, 2006.
[82] T. M. Katona, D. P. O’Malley, L. Cheng et al., “Loss of
heterozygosity analysis identiﬁes genetic abnormalities in
mycosis fungoides and speciﬁc loci associated with disease
progression,” American Journal of Surgical Pathology, vol. 31,
no. 10, pp. 1552–1556, 2007.
[83] N. H. Kim, S. Jeon, H. J. Lee, and A. Y. Lee, “Impaired
PI3K/Akt activation-mediated NF-κB inactivation under ele-
vated TNF-α is more vulnerable to apoptosis in vitiliginous
keratinocytes,” Journal of Investigative Dermatology, vol. 127,
no. 11, pp. 2612–2617, 2007.
[84] C. Eng, “PTEN: one gene, Many syndromes,” Human Muta-
tion, vol. 22, no. 3, pp. 183–198, 2003.
[85] C. Romano, “Genetics of PTEN hamatoma tumor syndrome
(PHTS),” in Neurocutaneous Disorders. Phakomatoses and
Hamartoneoplastis Syndromes, M. Ruggieri, I. Pascual Castro-
viejo, and C. Di Rocco, Eds., Springer, 2008.
[86] C. Hildenbrand, W. H. C. Burgdorf, and S. Lautenschlager,
“Cowdensyndrome—diagnosticskinsigns,”Dermatology,vol.
202, no. 4, pp. 362–366, 2001.
[87] Y. M. C. Hendriks, J. T. C. M. Verhallen, J. J. Van der
Smagt et al., “Bannayan-Riley-Ruvalcaba syndrome: further
delineation of the phenotype and management of PTEN
mutation-positivecases,”FamilialCancer,vol.2,no.2,pp.79–
85, 2003.
[88] E. Satter, “Proteus syndrome: 2 Case reports and a review or
the literature,” Cutis, vol. 80, no. 4, pp. 297–302, 2007.
[89] C. Schepis, D. Greco, M. Siragusa, and C. Romano, “Cere-
briform plantar hyperplasia: The major cutaneous feature of
Proteus syndrome,” International Journal of Dermatology, vol.
47, no. 4, pp. 374–376, 2008.